Myelodysplastic Syndromes

MDS are clonal hematopoietic disorders involving morphologic defects and peripheral-blood cytopenias, with a risk of progression to acute myeloid leukemia. Except for del(5q) MDS, which is responsive to lenalidomide, these disorders are largely managed with supportive care.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-10, Vol.383 (14), p.1358-1374
1. Verfasser:	Cazzola, Mario
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Age Anemia Azacitidine - therapeutic use Blood Bone marrow Classification Cloning Decitabine - therapeutic use Deoxyribonucleic acid Disease DNA DNA methylation Enzyme Inhibitors - therapeutic use Epigenetics Erythrocyte Transfusion Genes Genetic Predisposition to Disease Humans Immunotherapy Kinases Leukemia, Myeloid, Acute Mutation Myelodysplastic syndrome Myelodysplastic syndromes Myelodysplastic Syndromes - diagnosis Myelodysplastic Syndromes - genetics Myelodysplastic Syndromes - physiopathology Myelodysplastic Syndromes - therapy Myeloid leukemia Peripheral blood Stem Cell Transplantation Stem cells Targeted cancer therapy Transplantation, Homologous Tumors Watchful Waiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	MDS are clonal hematopoietic disorders involving morphologic defects and peripheral-blood cytopenias, with a risk of progression to acute myeloid leukemia. Except for del(5q) MDS, which is responsive to lenalidomide, these disorders are largely managed with supportive care.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMra1904794